SCHEMBL5723313

SCHEMBL5723313

CSc1ccc(-c2ccccc2C(O)c2cccc(F)c2)cc1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGS1 P23219 1/20 0.36
ALDH1A1 P00352 1/20 0.36
ESR1 P03372 1/20 0.36
MAPK14 Q16539 3/20 0.35
BRD4 O60885 2/20 0.35
FAAH O00519 1/20 0.35
MAPK13 O15264 1/20 0.35
MAPK12 P53778 1/20 0.35
MAPK11 Q15759 1/20 0.35
CES2 O00748 1/20 0.35
CES1 P23141 1/20 0.35
EPHX1 P07099 1/20 0.34
SLC6A2 P23975 2/20 0.34
SLC6A4 P31645 2/20 0.34
IGFBP3 P17936 1/20 0.34
PTPN5 P54829 1/20 0.34
CREBBP Q92793 1/20 0.34
GCGR P47871 2/20 0.33
AKR1C3 P42330 1/20 0.33
AKR1C2 P52895 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL230603 0.80 ALDH1A1 (0.42) ALDH1A1ESR1BRD4CES2CES1
SCHEMBL5723821 0.80 PTGS2 (0.41) PTGS1ALDH1A1ESR1BRD4CREBBP
SCHEMBL5723318 0.80 PTGS2 (0.54) PTGS1
SCHEMBL22414012 0.73 BACE1 (0.45) ALDH1A1PTPN5
SCHEMBL14528193 0.72 GAA (0.53) BRD4CES2CES1SLC6A2SLC6A4
SCHEMBL229877 0.72 CES2 (0.45) BRD4CES2CES1SLC6A2SLC6A4
SCHEMBL5723321 0.70 HDAC4 (0.35) BRD4CES2CES1SLC6A2SLC6A4
SCHEMBL28757199 0.70 CA12 (0.53) PTGS1ALDH1A1SLC6A2SLC6A4
SCHEMBL14415719 0.70 SLC6A2 (0.44) PTGS1ALDH1A1BRD4CES2CES1
SCHEMBL6721530 0.69 PTGS1 (0.59) PTGS1ALDH1A1MAPK14MAPK13MAPK12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1406609-B1 SUBSTITUTED ARYL COMPOUNDS AS NOVEL CYCLOOXYGENASE-2 SELECTIVE INHIBITORS, COMPOSITIONS AND METHODS OF USE NITROMED INC (US) 2006-09-06 EP disclosed
US-20050059665-A1 Substituted aryl compounds as novel cyclooxygenase-2 selective inhibitors, compositions and methods of use NITROMED, INC. (US) 2005-03-17 US disclosed
US-6825185-B2 IMPROVING THE CARDIOVASCULAR PROFILE OF A COX-2 SELECTIVE INHIBITOR BY ADMINISTERING WITH 3-HYDROXY-3- METHYLGLUTARYL COENZYME A, AN ANTIPLATELET AGENT, A THROMBIN INHIBITOR OR A THROMBOXANE INHIBITOR NITROMED, INC. 2004-11-30 US disclosed
US-20040116431-A1 Substituted aryl compounds as novel cyclooxygenase-2 selective inhibitors, compositions and methods of use NITROMED, INC. (US) 2004-06-17 US disclosed
US-6706724-B2 ANTITUMOR AGENTS; ANTIINFLAMMATORY AGENTS; ANALGESICS; ANTIPYRETIC AGENT NITROMED, INC. 2004-03-16 US disclosed
US-20020119977-A1 Substituted aryl compounds as novel cyclooxygenase-2 selective inhibitors, compositions and methods of use related applications NICOX S.A. (FR) 2002-08-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050059665-A1 Substituted aryl compounds as novel cyclooxygenase-2 selective inhibitors, compositions and methods of use PTGES, PTGER4, PTGS1 PTGS1 3/4885ALDH1A1 344/4885ESR1 1015/4885
US-20020119977-A1 Substituted aryl compounds as novel cyclooxygenase-2 selective inhibitors, compositions and methods of use related applications PTGS2, PTGES2, PTGES PTGS1 6/4885ALDH1A1 643/4885ESR1 1536/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.